Q-omics provides the consensus-scored SPAST profile across patient tissues and cancer cell-line models. SPAST expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SPAST is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, SPAST protein abundance shows 27,419 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, BLCA, and LSCC as cancer lineages where SPAST shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPAST — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPAST survival associations across molecular data types. SPAST RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPAST RNA expression–survival associations across cancer types. High SPAST expression shows unfavorable associations in LIHC, KIRP, ACC and UVM, but favorable associations in LUSC and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SPAST RNA expression.
This table summarizes SPAST tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SPAST. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPAST shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, KIRC, LUSC and STAD. The BLCA box plot shows higher SPAST RNA expression in tumor versus normal tissue (log2 FC = +1.042, t-test p < 0.001).
This table shows molecular features associated with SPAST in patient tissues and cancer cell lines. In patient samples, SPAST shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPAST RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
